Imaging Facilities

MRI imaging

The LCBRU is equipped with state of the art imaging facilities including:

  • A dedicated research NIHR funded 3T MRI scanner (Siemens Skyra), installed in 2011
  • Access to a 1.5T clinical cardiac scanner (Siemens Avanto).
  • A 16 slice CT scanner on site and a 64 slice CT scanner within the UHL Trust, with a new 128 dual source CT scanner.
  • Two SPECT scanners with ECG gating for cardiac scanning and a mobile PET/CT scanner
  • A research 2-D/3-D transthoracic ultrasound system (Philips IE33) with integrated carotid/vascular scanning, state of the art stress, strain and speckle tracking software. Scan analysis is available on-line (QLAB software) and off-line within the accompanying Xcelera reporting system.
  • Access to further advanced imaging facilities, including Electron Microscopy is available through our links with Leicester Imaging Technologies (LITE).

Highlighted Imaging Research

Tricuspid (top) and bicuspid (bottom) aortic valve with aortic stenosisWe conduct a vibrant portfolio of research using Cardiovascular Magnetic Ressonance Imaging (CMR), which is led by Dr Gerry McCann. Our main areas of CMR research are:

  • CMR as an outcome measure in clinical trials. CMR offers unique opportunities to characterise myocardial infarction (MI) – commonly known as a heart attack - by allowing us precisely measure the heart and quantify any changes to it as a result of treatment.
  • Better understanding of the causes of heart disease using advanced CMR techniques. Research within the LCBRU includes studies of patients with asymptomatic aortic stenosis (narrowing of the aortic valve), with particular emphasis on measuring blood flow and scarring within the heart.
  • The role of CMR in the investigation of patients with known or suspected heart disease.  Two of the largest ever CMR trials are being conducted at Glenfield Hospital. The MR-Inform study (led by King’s College London) assesses whether patient with angina can be as safely and more cost-effectively managed by stress CMR than using invasive angiography.  The BHF funded CEMARC-2 trial assesses whether patients with suspected chest pain of cardiac origin are better managed with 3T stress CMR than either SPECT or NICE guidance.


Share this page:

Athena SWAN Silver Award